Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
TAK:NYSE
Takeda Pharmaceutical Co Ltd
USD 16,62
-0,36%
(-0,060) 1D
USD 16,62
0,00% (0,00)
After hours
Closed: 1 Mei, 16:00:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TAK...
Open
USD 16,64
High
USD 16,71
Low
USD 16,55
Mkt. cap
52,10 mjd
Volume
1,28 m
Dividend
3,98%
Quarterly dividend
USD 0,17
Ex dividend date
29 Sep. 2025
P/E ratio
72,03
52-wk high
USD 18,90
52-wk low
USD 12,99
EPS
USD 0,23
Beta
0,02
Shares outstanding
3,18 mjd
No. of employees
47 k
News stories
From sources across the web
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOChristophe Weber | Christophe Weber
Employees47,5 k
Founded12 Jun. 1781
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Last report
29 Jan. 2026
Fiscal Period
Q3 2026
Normalized EPS / Estimate
149,00/ -JPY
0,00%miss
Revenue / Estimate
1,19 bn/ (1,20 bn est.)JPY
-0,83%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Mrt. 2025
Jun. 2025
Sep. 2025
Des. 2025
Revenue
1,05 bn
1,11 bn
1,11 bn
1,19 bn
Cost of goods sold
373,28 mjd
384,68 mjd
380,06 mjd
401,15 mjd
Cost of revenue
373,28 mjd
384,68 mjd
380,06 mjd
401,15 mjd
Research and development expenses
216,01 mjd
143,89 mjd
161,48 mjd
175,23 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
295,83 mjd
255,88 mjd
253,55 mjd
282,78 mjd
Operating expense
557,10 mjd
535,14 mjd
562,57 mjd
661,30 mjd
Total operating expenses
930,38 mjd
919,82 mjd
942,63 mjd
1,06 bn
Operating income
123,02 mjd
186,86 mjd
170,17 mjd
129,25 mjd
Other non operating income
-24,86 mjd
-77,96 mjd
77,96 mjd
-294,52 mjd
EBT including unusual items
-107,30 mjd
150,63 mjd
28,17 mjd
133,86 mjd
EBT excluding unusual items
100,18 mjd
152,93 mjd
128,86 mjd
114,17 mjd
Income tax expense
-4,20 mjd
26,35 mjd
39,90 mjd
30,13 mjd
Effective tax rate
3,92%
17,49%
141,64%
22,51%
Other operating expenses
-91,26 mjd
6,03 mjd
16,12 mjd
67,13 mjd
Net income
-103,16 mjd
124,24 mjd
-11,80 mjd
103,64 mjd
Net profit margin
-9,79%
11,23%
-1,06%
8,70%
Earnings per share
-
-
-
-
Interest and investment income
9,85 mjd
73,76 mjd
43,92 mjd
278,65 mjd
Interest expense
-7,82 mjd
-29,20 mjd
-161,10 mjd
-
Net interest expenses
2,03 mjd
44,56 mjd
-117,18 mjd
278,65 mjd
Depreciation and amortization charges
-
-
-
-
EBITDA
221,72 mjd
368,50 mjd
355,15 mjd
182,70 mjd
Gain or loss from assets sale
-2,39 mjd
-17,32 mjd
303,00 m
358,00 m
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer